New drug ALN-AGT01 RVR tested in healthy people for safety
NCT ID NCT06675565
First seen Sep 30, 2025 · Last updated May 26, 2026 · Updated 27 times
Summary
This early-stage study tested the safety and how the body processes a single dose of ALN-AGT01 RVR in 42 healthy adults. Participants received either the drug or a placebo, and researchers monitored for side effects and drug levels in blood and urine. The goal was to gather initial safety data, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinical Trial Site
Montreal, Canada
Conditions
Explore the condition pages connected to this study.